Correction to: Inhibitory effects of tea polyphenols by targeting cyclooxygenase-2 through regulation of nuclear factor kappa B, Akt and p53 in rat mammary tumors [0.03%]
题为“茶多酚通过调节核因子κB、Akt和p53靶向环氧合酶-2抑制大鼠乳腺肿瘤的作用”的校正文章
Preeti Roy,Jasmine George,Smita Srivastava et al.
Preeti Roy et al.
The authors regret to inform that there were unknowing errors in figures. The corrected images are given below. These figures are not affecting the results and conclusion of the manuscript. Hence, the text in original paper remains unchange...
Published Erratum
Investigational new drugs. 2019 Dec;37(6):1310-1311. DOI:10.1007/s10637-019-00841-0 2019
A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors [0.03%]
AT-101（BH3模拟物）联合紫杉醇和卡铂治疗实体瘤的I期临床试验
Mark N Stein,Susan Goodin,Murugeson Gounder et al.
Mark N Stein et al.
Background AT-101 is a BH3 mimetic that inhibits the heterodimerization of Bcl-2, Bcl-xL, Bcl-W, and Mcl-1 with pro-apoptotic proteins, thereby lowering the threshold for apoptosis. This phase I trial investigated the MTD of AT-101 in combi...
A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors [0.03%]
AT-101（BH3模因）联合紫杉醇和卡铂治疗实体肿瘤Ⅰ期临床研究
Mark N Stein,Susan Goodin,Murugeson Gounder et al.
Mark N Stein et al.
Background AT-101 is a BH3 mimetic that inhibits the heterodimerization of Bcl-2, Bcl-xL, Bcl-W, and Mcl-1 with pro-apoptotic proteins, thereby lowering the threshold for apoptosis. This phase I trial investigated the MTD of AT-101 in combi...
Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma [0.03%]
DEDN6526A抗内皮素受体抗体药物偶联物I期临床研究：针对转移性或不可切除的皮肤黏膜黑色素瘤及脉络膜黑色素瘤患者的研究
Shahneen Sandhu,Catriona M McNeil,Patricia LoRusso et al.
Shahneen Sandhu et al.
Background Endothelin B receptor (ETBR) is involved in melanoma pathogenesis and is overexpressed in metastatic melanoma. The antibody-drug conjugate DEDN6526A targets ETBR and is comprised of the humanized anti-ETBR monoclonal antibody con...
Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma [0.03%]
DEDN6526A抗内皮素B受体抗体药物偶联物I期临床研究用于治疗转移性或不可切除的皮肤黏膜黑色素瘤和葡萄膜黑色素瘤患者
Shahneen Sandhu,Catriona M McNeil,Patricia LoRusso et al.
Shahneen Sandhu et al.
Background Endothelin B receptor (ETBR) is involved in melanoma pathogenesis and is overexpressed in metastatic melanoma. The antibody-drug conjugate DEDN6526A targets ETBR and is comprised of the humanized anti-ETBR monoclonal antibody con...
Efficacy of immune checkpoint blockade in MUTYH-associated hereditary colorectal cancer [0.03%]
免疫检查点抑制剂在MUTYH基因相关遗传性结直肠癌中的疗效
Nikita M Volkov,Grigoriy A Yanus,Alexandr O Ivantsov et al.
Nikita M Volkov et al.
Colorectal carcinomas (CRCs) caused by hereditary biallelic MUTYH gene mutations are characterized by elevated mutation load and high lymphocyte infiltration. Given that these tumor features are associated with the response to immune checkp...
Ibrutinib as a potential therapeutic option for HER2 overexpressing breast cancer - the role of STAT3 and p21 [0.03%]
伊布替尼作为HER2过表达型乳腺癌潜在治疗选择的可能作用机制-STAT3和P21的作用
Chandra Bose Prabaharan,Allan Boyao Yang,Divya Chidambaram et al.
Chandra Bose Prabaharan et al.
Treatment response rates to current anticancer therapies for HER2 overexpressing breast cancer are limited and are associated with severe adverse drug reactions. Tyrosine kinases perform crucial roles in cellular processes by mediating cell...
Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma [0.03%]
AMG 232(AMG 820)治疗成人PTCH基因野生型晚期实体瘤或多发性骨髓瘤的I期临床试验
W Larry Gluck,Mrinal M Gounder,Richard Frank et al.
W Larry Gluck et al.
Background This open-label, first-in-human, phase 1 study evaluated AMG 232, an oral selective MDM2 inhibitor in patients with TP53 wild-type (P53WT), advanced solid tumors or multiple myeloma (MM). Methods In the dose escalation (n = 39), ...
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer [0.03%]
Wnt通路抑制剂Vantictumab联合白蛋白结合型紫杉醇和吉西他滨治疗以前未经过治疗的转移性胰腺癌患者的Ib期剂量递增研究
S Lindsey Davis,Dana B Cardin,Safi Shahda et al.
S Lindsey Davis et al.
Vantictumab is a fully human monoclonal antibody that inhibits Wnt pathway signaling through binding FZD1, 2, 5, 7, and 8 receptors. This phase Ib study evaluated vantictumab in combination with nab-paclitaxel and gemcitabine in patients wi...
Stimulation of neuroendocrine differentiation in prostate cancer cells by GHRH and its blockade by GHRH antagonists [0.03%]
生长激素释放激素对前列腺癌细胞神经内分泌分化的刺激作用及其拮抗剂的阻断作用
Laura Muñoz-Moreno,María J Carmena,Andrew V Schally et al.
Laura Muñoz-Moreno et al.
Prostate cancer is the second leading cause of cancer-related deaths among men in developed countries. Neuroendocrine prostate cancer, in particular, is associated with an aggressive phenotype and a poor prognosis. Neuroendocrine cells prod...